FRACTYL HEALTH INC (GUTS) Stock News

USA - Nasdaq - NASDAQ:GUTS - US35168W1036 - Common Stock

2.05 USD

+0.07 (+3.54%)

Last: 12/5/2025, 2:22:42 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

GUTS Latest News, Press Relases and Analysis

All

Press Releases

3 days ago - By: Benzinga

Fractyl Health's Revita Procedure Helps Patients Keep Weight Off After Stopping GLP-1 Drugs

3 days ago - By: Fractyl Health, Inc.

Fractyl Health Reports Positive 6-Month REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure

3 days ago - By: Fractyl Health, Inc.

Fractyl Health Reports Positive 6-Month REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure

4 days ago - By: Fractyl Health, Inc.

Fractyl Health to Participate in the 8th Annual Evercore Healthcare Conference

4 days ago - By: Fractyl Health, Inc.

Fractyl Health to Participate in the 8th Annual Evercore Healthcare Conference

24 days ago - By: Benzinga

Preview: Fractyl Health's Earnings

2 months ago - By: Stocktwits - Mentions: IWC VXF

News Image

GUTS Stock Rallied About 28% Today – Here’s Why

22 days ago - By: The Motley Fool

Fractyl (GUTS) Q3 2025 Earnings Call Transcript

23 days ago - By: Fractyl Health, Inc.

Fractyl Health Reports Third Quarter 2025 Results; Revita® Clinical Momentum Builds Toward 2026 Pivotal Readout and PMA Filing, Cash Runway Extended into Early 2027

a month ago - By: Fractyl Health, Inc.

Fractyl Health to Report Third Quarter 2025 Financial Results and Provide Business Updates on November 12, 2025

a month ago - By: Fractyl Health, Inc.

Fractyl Health to Report Third Quarter 2025 Financial Results and Provide Business Updates on November 12, 2025

4 months ago - By: The Motley Fool

Fractyl Health Posts 62% Wider Q2 Loss

2 months ago - By: Fractyl Health, Inc.

Fractyl Health Announces Potent Preclinical Results from RJVA-002, a Dual GIP/GLP-1 Gene Therapy Candidate for Obesity

2 months ago - By: Fractyl Health, Inc.

Fractyl Health Announces Potent Preclinical Results from RJVA-002, a Dual GIP/GLP-1 Gene Therapy Candidate for Obesity

2 months ago - By: Fractyl Health, Inc.

Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock

2 months ago - By: Fractyl Health, Inc.

Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock

2 months ago - By: Fractyl Health, Inc.

Fractyl Health Announces Groundbreaking Data from REMAIN-1 Midpoint Cohort Showing Revita® Maintained Weight Loss After GLP-1 Discontinuation

2 months ago - By: Fractyl Health, Inc.

Fractyl Health Announces Groundbreaking Data from REMAIN-1 Midpoint Cohort Showing Revita® Maintained Weight Loss After GLP-1 Discontinuation

3 months ago - By: Fractyl Health, Inc.

Fractyl Health Expands Board of Directors with Appointments of Industry Leaders to Advance Clinical Execution and Strategic Growth

3 months ago - By: Fractyl Health, Inc.

Fractyl Health Expands Board of Directors with Appointments of Industry Leaders to Advance Clinical Execution and Strategic Growth

4 months ago - By: Fractyl Health, Inc.

Fractyl Health Announces Second Quarter 2025 Financial Results and Business Updates

4 months ago - By: Fractyl Health, Inc.

Fractyl Health Announces Second Quarter 2025 Financial Results and Business Updates

4 months ago - By: Fractyl Health, Inc.

Fractyl Health Announces Closing of $23 Million Underwritten Public Offering Including Full Exercise of Underwriter’s Option to Purchase Additional Shares

4 months ago - By: Fractyl Health, Inc.

Fractyl Health to Report Second Quarter 2025 Financial Results and Provide Business Updates on August 12, 2025, and Will Participate in an Upcoming Investor Conference

4 months ago - By: Fractyl Health, Inc.

Fractyl Health to Report Second Quarter 2025 Financial Results and Provide Business Updates on August 12, 2025, and Will Participate in an Upcoming Investor Conference